



15w/1645

Hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on September 27, 2006

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

INFORMATION DISCLOSURE
STATEMENT

Examining Group 1645
Patent Application
Docket No. C&R-102
Serial No. 10/537,142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1645
Applicants : Richard Joseph Fagan, Christopher Benjamin Phelps, Tania Maria Rodrigues, Melanie Yorke, Mariastella De Tiani
Serial No. : 10/537,142
Filed : June 2, 2005
Conf. No. : 1704
For : Splice Variant of the Human Pituitary Growth Hormone

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. §371. The applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notification of Acceptance of the Application under 35 U.S.C. §371 (Form PCT/DO/EO/903). The Notification does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. In accordance with 37 C.F.R. §1.56, the applicants hereby request that the references cited in the International Search Report and listed on the

attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of cited references



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/537,142
Filing Date	June 2, 2005
First Named Inventor	Richard Joseph Fagan
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	C&R-102

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Database OMIM "Review regarding the human growth hormone" retrieved from OMIM, database accession no. OMIM 139250.	
	R2	DENOTO, F.M. <i>et al.</i> "Human growth hormone DNA sequence and mRNA structure: possible alternative splicing" <i>Nucl. Acids Res.</i> , 1981, 9(15):3719-3730.	
	R3	LECOMTE, C.M. <i>et al.</i> "A new natural HGH variant-17.5 kd-produced by alternative splicing. An additional consensus sequence with might play a role in branchpoint selection" <i>Nucl. Acids Res.</i> , 1987, 15(16):6331-6348.	
	R4	MASUDA, N. <i>et al.</i> "Molecular cloning of cDNA encoding 20 kda variant human growth hormone and the alternative splicing mechanism" <i>Biochimica et Biophysica Acta. Gene Struct. Express.</i> , 1988, 949(20):125-131.	
	R5	PROCTER, A.M. <i>et al.</i> "The molecular genetics of growth hormone deficiency" <i>Human Genetics</i> , 1998, 103(3):255-272.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.